Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Novo Nordisk A/SNYSE: NVO

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns positive

Q2 FY2026 net change in cash was DKK 23.36B, compared with -DKK 20.5B a year earlier. Trailing-twelve-month net change in cash was DKK 26.05B. Over 3 fiscal years it compounded at +77.5% a year.

Context

  • Net change in cash amounted to 3.5% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near DKK 23.36B or moves back toward the trailing-twelve-month quarterly average of DKK 6.51B.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 23.36B+537.6% QoQ
Last fiscal yearDec 2025
DKK 10.81B+755.8% YoY
LTMJun 2026
DKK 26.05B+175.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+213.9%——
1 year+755.8%——
3-year CAGR+77.5%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

DKK · from the cash flow

Latest · FY2025
10.81B DKK
Year-over-year change
+755.8%

Net Change in Cash vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +175.7% is the 3rd highest of 10, against a peer median of -65.9%.
  • Net change in cash amounts to 7.9% of revenue for NVO, versus a peer median of 1.7%.
NVO Competitors
Net Change in Cash for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 26.05B DKK+175.7%+77.5%7.9%
SNYSanofiLTM Jun 2026€11.23B EUR-2141.9%-28.3%23.0%
AMGNAmgen Inc.LTM Jun 2026$5.96B USD+568.3%+99.2%15.6%
LLYEli Lilly and CompanyLTM Jun 2026$5.57B USD+3559.9%—7.0%
JNJJohnson & JohnsonLTM Sep 2026$1.32B USD-24.5%+130.3%1.3%
MRKMerck & Co., Inc.LTM Jun 2026$1.13B USD-65.9%-33.2%1.7%
GSKGSK plcLTM Jun 2026£760.69M GBP-270.9%-46.0%2.3%
PFEPfizer Inc.LTM Jun 2026$664M USD-214.1%—1.0%
AZNAstraZeneca PLCLTM Sep 2026$251.43M USD-106.9%—0.4%
ABBVAbbVie Inc.LTM Jun 2026$102M USD+101.5%-18.5%0.2%
Peer median (excluding NVO) —-65.9%-23.4%1.7%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.